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SARS-CoV-2 is an emergent virus responsible for the coronavirus disease 2019 (COVID-19)
outbreak. Reported neurologic manifestations associated with SARS-CoV-2 include hyposmia,
headache, and consciousness disturbances.1 We describe 2 patients with COVID-19 presenting
with ophthalmoparesis and characteristic MRI findings.
Case description
Case 1
A 60-year-old woman presented with diplopia and right hemicranial headache after 10 days of
fever, hyposmia, nausea, and cough. Neurologic examination revealed right abducens nerve
palsy. The patient was hypoxemic (PaO2 67 mm Hg) in the absence of dyspnea. Blood
investigations showed lymphopenia (430/μL) and increased C-reactive protein (C-RP; 85 mg/
L), with thiamine, pyridoxine, and D-dimer levels within the normal range. Chest x-ray revealed
bilateral pneumonia. CSF showed 1 cell/mm3, normal protein levels (0.32 g/L), and elevated
lactic acid dehydrogenase (LDH; 54 U/L). SARS-CoV-2 RNA was detected by RT-PCR in
a nasopharyngeal swab specimen but not in CSF. Antiganglioside antibodies were negative, and
oligoclonal bands were not detected in the CSF. Brain MRI (figure 1, A–D and figure e-1 links.
lww.com/NXI/A276) showed diffuse fluid-attenuated inversion recovery (FLAIR)/T2-
hyperintensity (HI) in the pontine tegmentum and focal HI in the right VI cranial nerve
nuclei. The mammillary bodies and hypothalamus were HI, the pituitary gland was enlarged,
and the upper pituitary stalk seemed globular. Treatment with hydroxychloroquine and azi-
thromycin was started. Diplopia persisted 1 month after admission.
Case 2
A 35-year-old woman with a history of bulimia and a 3-week history of vomiting was admitted.
During her hospital stay, she developed diplopia and paresthesia. Vomiting disappeared few
days after admission, and she was discharged. Three days later, the patient presented with
progressive encephalopathy and was again admitted. She had neither fever nor respiratory
symptoms. Neurologic examination showed decreased arousal, disorientation, episodic mem-
ory deficits, bilateral abducens nerve palsy, and mild paraparesis with normal reflexes. Hyp-
oxemia (PaO2 61 mmHg), decreased lymphocytes (740/μL), increased C-RP (42 mg/L), and
creatinine kinase (346 U/L) were detected; LDH, D-dimer, thiamine, pyridoxine, and ion levels
were within the normal range. CSF revealed 0.53 g/L proteins, 2 cell/mm3, and normal LDH.
Chest x-ray was normal. SARS-CoV-2 RNAwas detected by RT-PCR in a nasopharyngeal swab
specimen but not in CSF. Anti-AQP4 and antiganglioside antibodies were negative, and oli-
goclonal bands were not detected in the CSF. MRI (figure 1, E–H and figure e-1) demonstrated
T2/FLAIR HI in the brainstem, including the VI cranial nerve nuclei, thalami, medial temporal
lobes, mammillary bodies, and hypothalamus. The upper pituitary stalk seemed swollen andHI.
The patient was diagnosed with Wernicke encephalopathy (WE) and was supplemented with
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thiamine and pyridoxine despite normal vitamin levels. The
patient’s mental status partially improved during the following
days. A control MRI (1 week after) also demonstrated partial
improvement of the MRI findings. After 1 month, oph-
thalmoparesis and paraparesis as well as her mental status
improved, but she had persistent episodic memory loss and
depression.
Discussion
To our knowledge, these are the 2 first patients with COVID-
19 presenting with ophthalmoparesis and involvement of the
hypothalamus and mesencephalic tegmentum with some ra-
diologic features resembling those of WE.2 However, thia-
mine levels in both our patients were normal, and there was
no condition leading to thiamine deficiency in patient 1 and
some radiologic features in case 2 (limbic involvement) were
not typical of WE. Concurrency of both patients, both di-
agnosed with COVID-19, and the important hypothalamic
involvement suggested a relationship with the underlying
infection. Other cases of ophthalmoparesis associated with
COVID-19 have recently been reported,3,4 one of them with
enlargement and contrast enhancement of the oculomotor
nerve that we did not observe in our patients. Acute hemor-
rhagic necrotizing encephalopathy has also been reported in
association with confirmed COVID-19 on MRI.5 Similarly,
encephalomyelitis associated with SARS-CoV-2 has been re-
cently reported in a patient with unconsciousness and
epileptic seizures in which SARS-CoV-2 was detected in the
CSF, and MRI demonstrated T2-HI in the right medial
temporal lobe.6 Our current cases show prominent hypo-
thalamus and pituitary stalk involvement on MRI. Indeed,
SARS-CoV (a related coronavirus causing the 2002–2004
SARS outbreak) has also been detected in hypothalamic
neurons of SARS autopsies,7 and hypothalamic-pituitary-
adrenal axis dysfunction has been observed in almost 40% of
SARS survivors, suggesting that SARS-CoV could cause
hypophysitis and/or hypothalamic damage.8 Furthermore,
animal models have shown that after intranasal inoculations,
SARS-CoV enters the brain through the olfactory bulb and via
the olfactory nerve with subsequent trans-synaptic spread,
causing selective neuronal infection and death in the absence
of inflammation in the amygdala, raphe nuclei, and paramedial
hypothalamus, a topographic distribution of lesions similar to
that from our cases.9 The olfactory bulb involvement is sup-
ported by the high rates of hyposmia in patients with COVID-
19 and would enable the trans-synaptic spread hypothesis.
However, other mechanisms, arising from the inflammatory
response or the metabolic demands to the susceptible regions,
could also be playing a role in the development of our
patients’ lesions.
In conclusion, we report 2 cases of COVID-19-associated neu-
rologic manifestations with abducens palsy, encephalopathy, and
characteristic MRI findings that suggest selective vulnerability of
the involved regions. Whether this vulnerability is related to
Figure 1 MRI findings in case 1 (A–D) and case 2 (E–H)
Case 1: (A) Sagittal fluid-attenuated inversion recovery (FLAIR) demonstrates an enlarged, hyperintense pituitary gland, thickened pituitary stalk, and
hyperintense hypothalamus. T2/FLAIR-hyperintensity (HI) is also seen in the dorsal midbrain and pons. (B) Sagittal postcontrast 3D magnetization-prepared
rapid gradient echo imaging T1 shows a heterogeneously enhancing pituitary and upper stalk. (C) Axial FLAIR shows HI in the tegmentum, involving the right
abducens nucleus. (D) Coronal FLAIR shows a hyperintense pituitary gland, prominent HI in the periventricular region of the III ventricle, and subtle HI in the
medial temporal lobes. Case 2: (E) Sagittal FLAIR demonstrates extensive HI in the hypothalamus and dorsal brainstem. (F) Axial FLAIR image shows HI and
swelling of the hypothalamus, mammillary bodies, and dorsal midbrain. (G) Axial FLAIR demonstrates HI in the tectum of the midbrain and subtle HI in the
medial temporal lobes. (H) Coronal FLAIR shows a prominent HI in the periventricular region of the III ventricle and in themammillary bodies, and subtle HI in
the medial temporal lobes.
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direct viral tropism, the inflammatory cascade, or to an increase
of local metabolic/vitamin demands remains to be elucidated.
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